Comprehensive analysis of body composition features in melanoma patients treated with tyrosine kinase inhibitors

Abstract

SummaryBackgroundThe introduction of tyrosine kinase inhibitors (TKI) has greatly improved the management of metastatic melanoma. Recent studies have uncovered a relationship between the body mass index (BMI) and outcome of patients with metastatic melanoma. However, conflicting results have challenged the relevance of this finding. In the current work, we aim to dissect body composition features of melanoma patients treated with TKI to evaluate their value as biomarkers.Patients and MethodsWe analyze body composition features via CT scans in a retrospective cohort of 57 patients with non‐resectable stage III/IV melanoma receiving first‐line treatment with TKI in our department, focusing on the impact of body composition on treatment efficacy and occurrence of adverse events.ResultsIn uni‐ and multivariate analyses, we identify an association between the visceral adipose tissue gauge index (VATGI) and survival. We furthermore profile additional body composition features including sarcopenia, which was also associated with a shorter overall survival. Finally, we detected an enrichment of cases with fatigue in patients with low VATGI.ConclusionsOur study represents the first exploratory study evaluating the suitability of body composition measurements as biomarkers for melanoma patients treated with TKI. Our data suggest a putative use of VATGI as a biomarker predicting patient outcome.